Study: Epo is well tolerated in neonates with HIE

11/16/2012 | Medscape (free registration)

Early trial data showed erythropoietin, given in addition to hypothermia treatment, was well tolerated and may be neuroprotective for neonates with hypoxic-ischemic encephalopathy. Researchers at the University of California, San Francisco, said they plan to do a large randomized trial of Epo that will follow infants for two years to evaluate neurologic outcomes.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA